<DOC>
	<DOC>NCT00634920</DOC>
	<brief_summary>This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy</brief_summary>
	<brief_title>Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>First or second single renal transplant from deceased or living donor Exclusion criteria Recipient of organs other than a renal transplant Present malignancy (within the last 2 years) other than excised basal cell or squamous cell carcinoma of the skin Severe liver disease At the time of randomization 7 weeks after transplantation In addition to the above criteria the following must be met at time of randomization: Patients maintained on a triple immunosuppressive regime consisting of cyclosporine, Enteric coated mycophenolate, and corticosteroids Patients completed the first 7 weeks without experiencing any rejection Graft loss Low hemoglobin value, low number of white blood cells or platelets High cholesterol values Proteinuria Wound healing problems Current severe major local or systemic infection Renal insufficiency Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>De novo renal transplantation</keyword>
</DOC>